Literature DB >> 31446813

Perinatal outcomes of recurrent placental abruption.

Tomoyuki Kojima1, Mio Takami1, Ryosuke Shindo1, Yusuke Saigusa2, Etsuko Miyagi3, Shigeru Aoki1.   

Abstract

INTRODUCTION: The purpose of this study was to classify patients with placental abruption (PA) into those with a history of PA (recurrence group) and those without a history (first-occurrence group), and compare the two groups to investigate whether perinatal outcomes differ between first-time PA and recurrent PA.
MATERIALS AND METHODS: Subjects include 6475 patients diagnosed with PA from the Pregnancy Birth Registry System of the Japan Society of Obstetrics and Gynecology. Patients were classified into recurrence group and first-occurrence group. Perinatal outcomes were compared between 141 patients in the recurrence group and 705 patients in the first-occurrence group with 1:5 propensity score matching, adjusting for maternal age, history of smoking, pregnancy-induced hypertension, and premature rupture of membranes as covariates.
RESULTS: There were no cases of maternal mortality in either groups, and the perinatal mortality rate did not exhibit a significant difference. Gestational age at delivery was significantly earlier in the recurrence group than in the first-occurrence group (35.3 vs 37.9 weeks, p < .001). The rate of preterm delivery at less than both 32 and 37 weeks of gestation was significantly higher in the recurrence group. The rate of UmApH < 7.1 and 5 min Apgar score < 7 were significantly higher in the recurrence group (21 vs 13%, p = .020, 20% vs 10%, p = .003, respectively).
CONCLUSIONS: The results suggest that recurrent PA occurs at an earlier gestational age and follows a more severe course than the first occurrence of PA.

Entities:  

Keywords:  First occurrence; maternal outcomes; neonatal outcomes; placental abruption; recurrence

Mesh:

Year:  2019        PMID: 31446813     DOI: 10.1080/14767058.2019.1660766

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  1 in total

1.  Can 17 hydroxyprogesterone caproate (17P) decrease preterm deliveries in patients with a history of PMC or pPROM?

Authors:  Gal Cohen; Maya Shavit; Netanella Miller; Rimon Moran; Yael Yagur; Omer Weitzner; Michal Ovadia; Hanoch Schreiber; Gil Shechter-Maor; Tal Biron-Shental
Journal:  PLoS One       Date:  2022-05-12       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.